Breaking News

BioTime Names CEO of Asterias Biotherapeutics

June 12, 2014

Lichtinger brings 35 years of executive pharma experience

Pedro Lichtinger has been appointed president and chief executive officer of BioTime’s subsidiary Asterias Biotherapeutics, which was created for the acquisition of Geron Corp.’s clinical-stage stem cell therapeutic assets. Asterias’ lead clinical programs are its AST-OPC1 cell therapeutic for spinal cord injury, and its AST-VAC2 allogeneic dendritic cell cancer immunotherapy platform.
 
Mr. Lichtinger has served as a director of BioTime since August 2009, where he led the field of regenerative medicine. Mr. Lichtinger has 35 years of executive leadership experience in the pharma industry. Previously, he was president and chief executive officer of Optimer Pharmaceuticals, where he led the successful registration and commercialization of DIFICID (fidaxomicin). Prior to Optimer, Mr. Lichtinger held a series of management positions at Pfizer during a 25-year career, including serving as president of Pfizer’s Global Primary Care Unit. He also led Pfizer’s European operations as president of the group covering 27 countries and all Pfizer medicines.
 
"Pedro has the ideal mix of skills to lead Asterias in the next stage of its growth," said Michael D. West, Ph.D., BioTime’s chief executive officer. "His experience in shepherding medicines through clinical and regulatory processes to commercialization will be invaluable as Asterias moves forward with its plans to bring two of its product candidates into clinical trials. Pedro is also a seasoned business leader and manager whose long track record in building businesses and business alliances speaks for itself.”
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research